Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer

ClinicalTrials.gov ID: NCT05113966

Public ClinicalTrials.gov record NCT05113966. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 9:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Single-Arm, Open-Label Study of Trilaciclib Administered Prior to Sacituzumab Govitecan-hziy in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments, at Least One in the Metastatic Setting

Study identification

NCT ID
NCT05113966
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
G1 Therapeutics, Inc.
Industry
Enrollment
30 participants

Conditions and interventions

Interventions

  • Trilaciclib Drug
  • Sacituzumab Govitecan-hziy Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 7, 2021
Primary completion
Nov 9, 2023
Completion
Jun 12, 2024
Last update posted
Jan 28, 2025

2021 – 2024

United States locations

U.S. sites
22
U.S. states
12
U.S. cities
21
Facility City State ZIP Site status
Ironwood Physicians Chandler Arizona 85224
Comprehensive Blood & Cancer Center Bakersfield California 93309
Los Angeles Hematology Oncology Medical Group Los Angeles California 90017
Valkyrie Clinical Trials Los Angeles California 90067
UCLA Hematology/Oncology Parkside Santa Monica California 90404
PIH Health Whittier California 90602
Rocky Mountain Cancer Centers Denver Colorado 80220
Memorial Healthcare System Hollywood Florida 33021
Orlando Health Cancer Institute Orlando Florida 32806
Duly Health and Care Joliet Illinois 60435
New England Cancer Specialists Scarborough Maine 04704
Minnesota Oncology Hematology, P.A. Woodbury Minnesota 55125
Comprehensive Cancer Centers of Nevada Las Vegas Nevada 89128
Northwest Cancer Specialists, PC Tigard Oregon 97223
Texas Oncology - Austin Central Austin Texas 78731
Texas Oncology - Baylor Charles A. Sammons Cancer Center Dallas Texas 75246
Texas Oncology - Longview Cancer Center Longview Texas 75601
Inova Schar Cancer Institute Fairfax Virginia 22031
Virginia Oncology Associates Norfolk Virginia 23502
Oncology and Hematology Associates of Southwest Virginia, Inc Roanoke Virginia 24014
Multicare Health System Auburn Washington 98001
Northwest Medical Specialties, PLLC Tacoma Washington 98405

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05113966, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 28, 2025 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05113966 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →